trending Market Intelligence /marketintelligence/en/news-insights/trending/YvKf4DLwetu2OKMZsBc9zw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Approvals for Roche, AbbVie; designations for AstraZeneca, Akari Therapeutics

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Approvals for Roche, AbbVie; designations for AstraZeneca, Akari Therapeutics

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Aug. 16.

Approvals

* Roche Holding AG's Rozlytrek for non-small cell lung cancer that has spread to other parts of the body and who express ROS1.

* Roche's Rozlytrek, for patients whose solid tumors have certain gene rearrangements called NTRK gene fusion, that do not have a known acquired resistance mutation. The drug received accelerated approval for this indication.

* AbbVie Inc.'s Rinvoq, for adults with moderately to severely active rheumatoid arthritis who cannot take or have had an inadequate response to the commonly used immunosuppressive drug methotrexate.

* Celgene Corp.'s Inrebic for patients with intermediate or high-risk myelofibrosis. The approval was given to Celgene's life sciences arm Impact Biomedicines Inc.

* Zimmer Biomet Holdings Inc.'s product called the Tether, for children with scoliosis. The treatment got clearance under the FDA's humanitarian device exemption pathway.

* Expanded approval, for Edwards Lifesciences Corp. Sapien 3 and Sapien 3 Ultra along with Medtronic PLC's CoreValve Evolut R and CoreValve Evolut PRO transcatheter heart valves for patients with aortic stenosis who are at low risk of open-heart surgery.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: Associated Press

Fast track

* Windtree Therapeutics Inc.'s istaroxime for acute heart failure.

* Akari Therapeutics PLC's nomacopan for hematopoietic stem cell transplant associated thrombotic microangiopathy, or HSCT-TMA, in children.

Breakthrough therapy

* AstraZeneca PLC's Calquence as a single therapy for adults with chronic lymphocytic leukemia.

Other designations

* Qualified infectious disease product, for Daré Bioscience Inc.'s antibacterial gel DARE-BV1 for bacterial vaginosis.